N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Diabetic Neuropathic Arthropathy
Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml
Phase 3 N=61 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
Phase 3 N=7 Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Charcot Joint of Foot
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 7 Participants
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
N/A N=50 Effect of Educational Booklet for Foot-related Exercises for Prevention and Treatment in People With Diabetic Neuropathy
Diabetic Neuropathies
Primary: Change From Baseline Diabetic Neuropathy Symptoms at 8-weeks — 5.3; 6.2 units on a scale
N/A N=78 Effects of Foot Muscle Strengthening in Daily Activity in Diabetic Neuropathic Patients
Diabetic Neuropathies
Primary: Daily Physical Activity — 8744; 7373 number of steps per week
Phase 2 N=452 Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo — -1.86; -1.79; -2.04; -2.32…
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 2 N=180 Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy
Painful Diabetic Neuropathy
Primary: Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation — -1.9; -2.4; -1.5; -2.7 units on a scale — p=0.168
Phase 2 N=273 A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
Diabetic Neuropathy, Painful
Primary: Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks — -2.08; -2.22; -2.45; -2.42 units on a scale
N/A N=14 Electrical Stimulation in Diabetic Peripheral Neuropathy
NMES · Control
Primary: Nerve Conduction Speed (Common Peroneal Nerve) — 33.93; 44.1; 41.63; 44.13 m/sec
N/A N=45 Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy
Diabetic Neuropathy
Primary: Sural Nerve Amplitude — 1.22; 2.37; 0.88; 0.86 uV — p=0.49
N/A N=47 Cognitive Behavioral Therapy for Diabetic Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Numeric Rating Scale (NRS) Pain Intensity — -0.83; -0.45 units on a scale — p=0.47
Phase 3 N=811 A Study in Painful Diabetic Neuropathy
Diabetic Neuropathy, Painful
Primary: Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form — -2.353; -2.161 units on a scale — p=0.370
N/A N=46 Evaluation of Exenatide in Patients With Diabetic Neuropathy
Type 2 Diabetes Mellitus · Diabetic Peripheral Neuropathy
Primary: Confirmed Clinical Neuropathy (CCN) — 14; 18 participants
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
N/A N=72 Improving Neuropathy and Mobility in People With Early Diabetes
Diabetes · Physical Activity
Primary: Six Minute Walk (6MW) Test — 156.644156; 61.257846 feet
Phase 3 N=339 A Study for the Treatment of Diabetic Peripheral Neuropathic Pain
Diabetic Neuropathies
Primary: Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg) — -1.61; -2.47 units on a scale — p=<0.0001
Phase 2 N=226 Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Peripheral Neuropathy · Neuropathic Pain
Primary: Change From Baseline in Mean Numeric Pain Rating Scale (NPRS) Score — 1.02; 1.74; 1.51 units on a scale
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
N/A N=1,270 Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Change in Patient Quality of Life at Baseline and 8 Months — 0.66; 0.65; 0.68; 0.68 units on a scale
N/A N=140 Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Polyneuropathies · Obesity · Bariatric Surgery Candidate
Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15
Phase 2 N=128 Study of DA-9801 to Treat Diabetic Neuropathy
Diabetic Neuropathy
Primary: Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS) — 6.2; 6.6; 6.6; 6.5 Scores…
Phase 2 N=30 Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05